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Twice-Weekly Brincidofovir (CMX001) Shows Promising
Antiviral Activity in Immunocompromised Transplant
Recipients with Asymptomatic Adenovirus Viremia
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Herve Mommeja-Marin 4. 1 Cincinnati Children’s Hospital
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Background: Adenovirus (AdV) infection causes morbidity
and mortality in immunocompromised patients, particularly
in pediatric patients. There is no approved therapy for the
prevention, preemption or treatment of AdV infection.
Brincidofovir (BCV, CMX001), an orally bioavailable broad-
spectrum nucleotide analog, has demonstrated in vitropo-
tency against all AdV species tested, including those most
often associated with severe disease. Two recent clinical
trials initiated brincidofovir twiceweekly (BIW) in transplant
recipients who presented with AdV viremia and no evidence
of end-organ AdV disease.
Methods: Study 202 was a randomized, placebo-controlled
trial that evaluated BCV as preemptive treatment of asymp-
tomatic adenoviremia in hematopoietic cell transplant (HCT)
recipients. Study 350 was an open-label, expanded access
trial in immunocompromised patients with no alternative
therapeutic intervention. Adult subjects were treated with
BCV 100 mg BIW; pediatric subjects were treated with BCV 2
mg/kg BIW. AdV viremia was monitored weekly. Antiviral
responses and mortality results are reported.
Results: A total of 26 subjects in Study 202 (n¼14) and Study
350 (n¼12) received BCV BIW based on AdV viremia at
screening. Subjects ranged from 7 months to 68 years of age
and all but one were HCT recipients. AdV was detected at the
central laboratory in 21 subjects at the time of ﬁrst dose.
Baseline viremia (BL) ranged from 100 (the lower limit of
detection for the assay, LLOD) to 2.2 x 107 copies/mL (median
3700). AdV viremia decreased to LLOD for 67% (14 of 21)
subjects within the ﬁrst week of therapy; an additional 4
subjects (18 of 21, 86%) reached LLOD at some time during
treatment. High levels of AdV viremia (>1000 c/mL) detected
in 14 subjects decreased to LLOD in 79% (11 of 14) within a
median of 9 days of BCV, and with a mean decrease of 1.8
log10c/mL. Observed all-cause mortality during a median 8
weeks (range 3 to 47) of follow-up was 15% (4 of 26). Two of
the 4 subjects who died had undetectable AdV viremia at the
time of death.
Conclusions: High risk transplant patients receiving twice-
weekly brincidofovir had rapid decline in their AdV viremia,
with limited progression to all-cause mortality. BCV is a
promising therapy for AdV and further study is warranted.
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Brincidofovir (CMX001) Is Well Tolerated in Highly
Immunocompromised Pediatric Patients
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Medical Center, Omaha, NE; 6 Chimerix, Inc., Durham, NCBackground: Brincidofovir (BCV, CMX001) is a Phase 3
broad-spectrum antiviral in development for the prevention
of dsDNA viral infections in immunocompromised patients.
Since pediatric patients pose unique toxicity challenges and
dsDNA viral infections are common in this age group, we
undertook an analysis of the collective safety experience in
pediatric subjects receiving BCV.
Methods: All pediatric subjects (<18 years) received oral
BCV weekly or twice-weekly under EINDs, in the open-label
expanded access Study 350, and in placebo-controlled Study
202 for the preemptive treatment of adenovirus (AdV)
infection. In Study 202, BCV was administered with food and
guidance on the management of gastrointestinal (GI) dis-
turbances was provided to the investigators.
Results: 147 pediatric subjects (median 7 years, range 3
months to 17 years) received a median of 7 weeks of BCV
(range 1 to 44), with 45 subjects receiving at least 10 weeks
of 4 mg/kg/week. Subjects were predominantly hematopoi-
etic cell transplant (HCT) recipients. Consistent with data
from adult immunocompromised subjects, the most
frequently reported adverse events (AEs) were GI distur-
bances, with diarrhea of any grade reported in 48% of sub-
jects in Study 202 and 43% in Study 350 and EINDs. Grade 3/4
diarrhea was reported in 13% (Study 202) and 12% (Study
350) of subjects. Less than 10% of subjects across Studies 202
and 350 discontinued BCV for GI symptoms. Transient in-
creases in ALT were reported in 4% (Study 202) and 12%
(Study 350 and EINDs) of subjects, predominantly <5x ULN
(grade 2) and not requiring discontinuation of BCV. In Study
202, the incidence of GI and ALT events leading to study drug
discontinuation was not higher in the BCV group than in the
placebo group, although the interpretation of these data is
limited by the small sample size. Based on treatment emer-
gent laboratory abnormalities, no indications of renal toxicity
or hematologic toxicity including neutropenia were
observed, including subjects who received higher BCV dose
or longer durations of treatment.
Conclusions: A review of data from pediatric subjects
treated with brincidofovir did not indicate any previously
unidentiﬁed safety signals. In these subjects, as in adults,
there was no indication of hematologic or renal toxicity. The
safety and tolerability proﬁle in adults and pediatric patients
to date support the continued development of brincidofovir
as prevention for dsDNA viral diseases.107
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Introduction: CBT is now associated with comparable dis-
ease-free survival to that of adult donor transplantation.
However, given CB grafts lack memory T & B cells, the ability
of CBT recipients to respond to vaccines is of great interest.
Methods: We analyzed the proportion of surviving double-
unit CBT recipients undergoing vaccination & their responses
(seroconversion or >3x rise in titers) to primary series vac-
cines (tetanus, diphtheria, pertussis, H. inﬂuenzae, polio &
pneumococcus). Pneumococcal response was deﬁned as
Vaccine Children (n ¼ 18) Adults (n ¼ 45)
Tetanus 77% 63%
Diphtheria 79% 74%
Pertussis 92% 61%
Haemophilus inﬂ. B 88% 91%
Polio 85% 76%
Pneumococcus 60% 46%
Table 1
Timing of PCP infection after HSCT and differences among cases vs. controls
Factor <60 days 60-270 days >270 days
Proportion of PCP cases 26% 51% 24%
Bactrim prophylaxis* 36% vs. 35% 14% vs. 43% 11% vs. 21%
Grade 3-4 aGVHD* 29% vs. 17% 31% vs. 24% 42% vs. 21%
cGVHD* 79% vs. 44%
*Cases vs. controls; performed on nested case control analysis from data
collected on secondary forms of allo HSCT (n¼ 117).
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transplanted for hematologic malignancies with CNI/MMF
prophylaxis between 10/2005-2/2012. Vaccination criteria
were 1 year post-CBT (earlier in select children), CD4+
>200 cells/ul, & independence from IVIg.
Results: Of 132 patients transplanted, 41 died or relapsed
prior to 1-year. Of 91 remaining patients, 67 (74%) were
vaccinated of whom 63 were evaluable with titer responses.
GVHD was the most common reason for survivors not to be
vaccinated (18/91, 20%). Median age of 63 evaluable vaccine
recipients was 34 years (range 0.9-64); the median time to
vaccination was +17 months (range 7-45). Vaccination was
delayed in 39 CBTs with prior gr. II-IV acute &/or mod-severe
chronic GVHD (+17 months, range 9-45) compared to no
signiﬁcant prior GVHD (+14 months, range 7-33), & in 13
Rituximab (+19 months, range 12-45) recipients. Responses
to the primary series vaccines in children < 18 years & adults
are shown (Table). Responses were seen even in the setting
of prior GVHD or prior Rituximab. Immune function prior to
vaccination did not inﬂuence responses to pneumococcus, H.
inﬂuenza, pertussis or diphtheria vaccines. However, those
with recovery > median CD4+CD45RA+ (>127/ul) & CD19+
(> 793/ul) counts had increased likelihood of tetanus (p ¼
.09 & p ¼ .04) & polio (p ¼ .05 & p ¼ .02) responses. There
were no serious vaccine reactions & with a median 54 month
(range 22-96) follow-up of vaccinated patients, their survival
is 100%.
Conclusions: CBT recipients, including adults & those with
prior GVHD, are capable of responding to tetanus, diphtheria,
pertussis, H. Inﬂuenza, polio & pneumococcal conjugate
vaccines similar to reported adult donor allograft series.
Furthermore, our data suggests improved immune recovery
(CD4+45RA+ & CD19+ subsets) prior to vaccination can
augment vaccine efﬁcacy. However, GVHD can hinder the
ability to commence vaccines in long-term survivors. Addi-
tionally, the sub-optimal responses to non-live vaccines in
some recipients highlight the need to obtain pre- & post-
vaccine titers to document responses, investigate the optimal
timing & number of vaccines, & the role of boosters & CD27+
memory B-cell measurement to predict response.
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Pneumocystis jiroveci pneumonia (formerly PCP) is associ-
ated with high morbidity and mortality after HSCT. Little is
known about PCP infections after HSCT due to presumed
rarity of disease after the advent of prophylaxis. We report
results of a CIBMTR study evaluating the incidence, timing,
prophylaxis agents, risk factors, and mortality of PCP in
autologous (auto) and allogeneic (allo) HSCT recipients. For
recipients of ﬁrst HSCT captured between 1995 and 2005,
PCP infection was documented in 0.63% (n¼177) of allo
(n¼27,934) and 0.28% (n¼52) of auto (n¼18525) HSCT. After
allo-HSCT, cases were distributed early and late after HSCT
(Table 1). A nested case control study was performed con-
trolling for auto vs. allo, primary disease, and alive at PCP
diagnosis, to evaluate risk factors for PCP, the inﬂuence of
PCP prophylaxis agents on the risk of PCP, and the effect of
PCP on overall survival using supplemental data (n¼68 allo
cases, n¼111 allo controls). In univariate analysis, PCP
infection was higher among recipients who were not
Caucasian (p¼.001), received PB (vs. BM) (p¼.027), campath/
ATG (p ¼ .02), less well-matched grafts (p ¼ <.001), and had
lymphopenia (p<.001) or steroids (p <.001) in the 30 days
prior to PCP. Other risk factors are described by onset time of
PCP after HSCT (Table 1). Prophylaxis agents varied but the
use of Bactrim was lower in cases occurring late. There were
more cases with grade 3-4 acute GVHD and chronic GVHD vs.
controls. After allo HSCT, overall survival (OS) was signiﬁ-
cantly poorer among cases vs. controls [1 year: 41% vs. 73%
(p<.0001); 5 year: 25% vs. 56% (p<.0001)]. Similarly,
following auto HSCT, OS was lower in cases vs. controls
(1year: 42% vs. 86% (p¼.0004); 5 year: 13% vs. 52%
(p¼.0003)). After controlling for signiﬁcant variables (age,
disease status, GVHD prophylaxis, year of HSCT, aGVHD),
proportional hazards model revealed that PCP cases were
6.87x more likely to die vs. matched controls (p<.0001, CI
4.84-9.75). Thus, these data reveal that: PCP infection is rare
after HSCT; PCP occurs both early and late after HSCT;
mismatch, GVHD prophylaxis, and GVHD and steroids are
risk factors for PCP; and PCP infection is associated with
higher mortality rate after allo and auto HSCT. Furthermore,
our data suggest opportunities to improve supportive care,
starting PCP prophylaxis early post-HSCT and continuing for
those with these newly identiﬁed risk factors: GVHD, steroid
exposure, or poor immune reconstitution.CRA -DATA MANAGEMENT109
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